{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T14:20:41Z","timestamp":1704896441197},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T00:00:00Z","timestamp":1346889600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11936-012-0206-5","type":"journal-article","created":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T02:35:36Z","timestamp":1346812536000},"page":"665-678","source":"Crossref","is-referenced-by-count":4,"title":["Medical, Surgical and Interventional Management of Hypertrophic Cardiomyopathy With Obstruction"],"prefix":"10.1007","volume":"14","author":[{"given":"Sammy","family":"Elmariah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Fifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,6]]},"reference":[{"key":"206_CR1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199703133361107","volume":"336","author":"P Spirito","year":"1997","unstructured":"Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775\u201385.","journal-title":"N Engl J Med"},{"key":"206_CR2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/CIRCULATIONAHA.111.037135","volume":"124","author":"RM Gupta","year":"2011","unstructured":"Gupta RM, Weiner RB, Baggish AL, Fifer MA. Still a kid at heart: hypertrophic cardiomyopathy in the elderly. Circulation. 2011;124:857\u201363. This case provides a step-by-step approach to the clinical management of patients presenting with HOCM and cardiovascular symptoms, highlighting medical management techniques, SCD risk stratification, familial screening, and surgical septal reduction.","journal-title":"Circulation"},{"key":"206_CR3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.CIR.26.2.161","volume":"26","author":"E Braunwald","year":"1962","unstructured":"Braunwald E, Brockenbrough EC, Morrow AG. Hypertrophic subaortic stenosis\u2013a broadened concept. Circulation. 1962;26:161\u20135.","journal-title":"Circulation"},{"key":"206_CR4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.amjcard.2011.05.018","volume":"108","author":"PP Dimitrow","year":"2011","unstructured":"Dimitrow PP, Cotrim C, Cheng TO. Importance of upright posture during exercise in detection of provocable left ventricular outflow tract gradient in hypertrophic cardiomyopathy. Am J Cardiol. 2011;108:614.","journal-title":"Am J Cardiol"},{"key":"206_CR5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/CIRCULATIONAHA.107.694158","volume":"117","author":"MA Fifer","year":"2008","unstructured":"Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation. 2008;117:429\u201339.","journal-title":"Circulation"},{"key":"206_CR6","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1161\/CIR.0b013e318214876d","volume":"123","author":"V Fuster","year":"2011","unstructured":"Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269\u2013367.","journal-title":"Circulation"},{"key":"206_CR7","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","volume":"104","author":"I Olivotto","year":"2001","unstructured":"Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517\u201324.","journal-title":"Circulation"},{"key":"206_CR8","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.1161\/CIR.0b013e318223e2bd","volume":"124","author":"BJ Gersh","year":"2011","unstructured":"Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783\u2013831. These are the first ACCF\/AHA practice guidelines for the diagnosis and management of HCM.","journal-title":"Circulation"},{"key":"206_CR9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0002-9149(78)90687-2","volume":"42","author":"MJ Frank","year":"1978","unstructured":"Frank MJ, Abdulla AM, Canedo MI, Saylors RE. Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol. 1978;42:993\u20131001.","journal-title":"Am J Cardiol"},{"key":"206_CR10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0002-9149(94)90416-2","volume":"74","author":"MA Fifer","year":"1994","unstructured":"Fifer MA, O'Gara PT, McGovern BA, Semigran MJ. Effects of disopyramide on left ventricular diastolic function in hypertrophic cardiomyopathy. Am J Cardiol. 1994;74:405\u20138.","journal-title":"Am J Cardiol"},{"key":"206_CR11","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.amjcard.2010.06.059","volume":"106","author":"K Kajimoto","year":"2010","unstructured":"Kajimoto K, Imai T, Minami Y, Kasanuki H. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am J Cardiol. 2010;106:1307\u201312. This small (24-patient) but elegant study demonstrated the superiority of disopyramide over propranolol and verapamil in reducing LVOT obstruction at rest. In addition, the authors use the comparative efficacy of disopyramide and cibenzoline (combined sodium and calcium channel blockers), and pilsicainide (a pure sodium channel blocker) in reducing LV outflow gradient to identify sodium channel blockade as a therapeutic target for LVOT gradient reduction.","journal-title":"Am J Cardiol"},{"key":"206_CR12","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/j.jacc.2011.08.040","volume":"58","author":"W Ball","year":"2011","unstructured":"Ball W, Ivanov J, Rakowski H, Wigle ED, Linghorne M, Ralph-Edwards A, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011;58:2313\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"206_CR13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2009.09.047","volume":"55","author":"S Agarwal","year":"2010","unstructured":"Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;55:823\u201334. This meta-analysis includes12 observational studies comparing the efficacy of surgical myectomy to ASA. The study finds no significant difference between the 2 treatment modalities in regard to short- and medium-term mortality and to post-procedure functional status. However, ASA was associated with an higher risk of the need for permanent pacemaker implantation.","journal-title":"J Am Coll Cardiol"},{"key":"206_CR14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/CIRCINTERVENTIONS.109.916676","volume":"3","author":"RA Leonardi","year":"2010","unstructured":"Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv. 2010;3:97\u2013104. This meta-analysis includes observational studies evaluating clinical outcomes after ASA (19 studies) and\/or septal myectomy (eight studies). Unadjusted rates of all-cause mortality and SCD were similar between ASA and septal myectomy. After adjustment for differences in baseline patient characteristics, however, mortality was lower after ASA than after myectomy.","journal-title":"Circ Cardiovasc Interv"},{"key":"206_CR15","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/eurheartj\/ehr013","volume":"32","author":"MA Fifer","year":"2011","unstructured":"Fifer MA, Sigwart U. Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation. Eur Heart J. 2011;32:1059\u201364. This review article addresses the controversy surrounding ASA in addition to highlighting several advances in procedural techniques that have increased the safety of ASA and improved patient outcomes.","journal-title":"Eur Heart J"},{"key":"206_CR16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00059-006-2928-1","volume":"31","author":"F Cecchi","year":"2006","unstructured":"Cecchi F, Olivotto I, Nistri S, Antoniucci D, Yacoub MH. Midventricular obstruction and clinical decision-making in obstructive hypertrophic cardiomyopathy. Herz. 2006;31:871\u20136.","journal-title":"Herz"},{"key":"206_CR17","doi-asserted-by":"crossref","unstructured":"Chen J, Nagaraj H, Bhambhani P, Kliner DE, Soman P, Garcia EV, et al. Effect of alcohol septal ablation in patients with hypertrophic cardiomyopathy on left-ventricular mechanical dyssynchrony as assessed by phase analysis of gated SPECT myocardial perfusion imaging. Int J Cardiovasc Imaging. 2011 doi: 10.1007\/s10554-011-9942-y .","DOI":"10.1007\/s10554-011-9942-y"},{"key":"206_CR18","doi-asserted-by":"crossref","first-page":"H129","DOI":"10.1152\/ajpheart.00077.2011","volume":"301","author":"SA Timmer","year":"2011","unstructured":"Timmer SA, Knaapen P, Germans T, Dijkmans PA, Lubberink M, Ten Berg JM, et al. Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy. Am J Physiol Heart Circ Physiol. 2011;301:H129\u201337.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"206_CR19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/CIRCINTERVENTIONS.110.959718","volume":"4","author":"MK Jensen","year":"2011","unstructured":"Jensen MK, Almaas VM, Jacobsson L, Hansen PR, Havndrup O, Aakhus S, et al. Long-term outcome of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: a Scandinavian multicenter study. Circ Cardiovasc Interv. 2011;4:256\u201365. This multicenter study reports the medium-term outcomes of 313 ASA procedures performed in 279 patients. Improvements in LV outflow obstruction and functional status were sustained over mean follow-up 2.9\u00a0years. In addition, 10-year survival after ASA was similar to that of an age- and sex-matched population.","journal-title":"Circ Cardiovasc Interv"},{"key":"206_CR20","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.jacc.2011.06.073","volume":"58","author":"SF Nagueh","year":"2011","unstructured":"Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. J Am Coll Cardiol. 2011;58:2322\u20138. This large multicenter study including 874 patients who underwent ASA identified lower ejection fraction at baseline, smaller number of septal arteries injected with ethanol, higher number of ASA procedures per patient, greater septal thickness after ASA, and beta blocker use after ASA as independent predictors of postprocedural mortality.","journal-title":"J Am Coll Cardiol"},{"key":"206_CR21","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jcin.2011.02.014","volume":"4","author":"JB Geske","year":"2011","unstructured":"Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2011;4:704\u20139.","journal-title":"JACC Cardiovasc Interv."},{"key":"206_CR22","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jcin.2011.06.008","volume":"4","author":"A Almasood","year":"2011","unstructured":"Almasood A, Garceau P, Woo A, Rakowski H, Schwartz L, Overgaard CB. Time to significant gradient reduction following septal balloon occlusion predicts the magnitude of final gradient response during alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. JACC Cardiovasc Interv. 2011;4:1030\u20134.","journal-title":"JACC Cardiovasc Interv"},{"key":"206_CR23","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1161\/CIRCULATIONAHA.110.975599","volume":"123","author":"E Ghersin","year":"2011","unstructured":"Ghersin E, Soto V, Heldman AW. Multidetector computerized tomography can guide and document alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2011;123:e5\u20137.","journal-title":"Circulation"},{"key":"206_CR24","doi-asserted-by":"crossref","unstructured":"Krishnaswamy A, Tuzcu EM, Kapadia SR. Use of intraprocedural CT imaging to guide alcohol septal ablation of hypertrophic cardiomyopathy in the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2011.","DOI":"10.1002\/ccd.23418"},{"key":"206_CR25","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1136\/heartjnl-2011-300184","volume":"97","author":"JC Spratt","year":"2011","unstructured":"Spratt JC, Langrish JP. Identifying the target septal perforator prior to alcohol septal ablation in hypertrophic obstructive cardiomyopathy: a new application for computed tomography coronary angiography. Heart. 2011;97:1718\u20139.","journal-title":"Heart"},{"key":"206_CR26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.amjcard.2004.10.050","volume":"95","author":"J Veselka","year":"2005","unstructured":"Veselka J, Duchonova R, Prochazkova S, Palenickova J, Sorajja P, Tesar D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol. 2005;95:675\u20138.","journal-title":"Am J Cardiol"},{"key":"206_CR27","doi-asserted-by":"crossref","unstructured":"Fifer MA, Palacios I, Sanborn DMY, Sigwart U. Hypertrophic cardiomyopathy. In: Lanzer P, editor. Catheter-based Cardiovascular Interventions. Springer; In press.","DOI":"10.1007\/978-3-642-27676-7_42"},{"key":"206_CR28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.acvd.2011.05.006","volume":"104","author":"T Cuisset","year":"2011","unstructured":"Cuisset T, Franceschi F, Prevot S, Ansaldi S, Habib G, Pankert M, et al. Transradial approach and subclavian wired temporary pacemaker to increase safety of alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: the TRASA trial. Arch Cardiovasc Dis. 2011;104:444\u20139.","journal-title":"Arch Cardiovasc Dis"},{"key":"206_CR29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ccd.23161","volume":"78","author":"R Guo","year":"2011","unstructured":"Guo R, Qian J, Yang Y, Zhu Q, Liu D, Deng C, et al. A new strategy for septal ablation with transendocardial ethanol injection using a multifunctional intracardiac echocardiography catheter: a feasibility study in canines. Catheter Cardiovasc Interv. 2011;78:316\u201323.","journal-title":"Catheter Cardiovasc Interv"},{"key":"206_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.107.738740","volume":"118","author":"P Sorajja","year":"2008","unstructured":"Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118:131\u20139.","journal-title":"Circulation"},{"key":"206_CR31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2005.08.032","volume":"97","author":"AA Chen","year":"2006","unstructured":"Chen AA, Palacios IF, Mela T, Yoerger DM, Picard MH, Vlahakes G, et al. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2006;97:264\u20139.","journal-title":"Am J Cardiol"},{"key":"206_CR32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jtcvs.2011.10.059","volume":"143","author":"HV Schaff","year":"2012","unstructured":"Schaff HV, Dearani JA, Ommen SR, Sorajja P, Nishimura RA. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: Results of operation in patients with latent obstruction. J Thorac Cardiovasc Surg. 2012;143:303\u20139. The authors review the results of septal myectomy in 249 patients who had latent obstruction with minimal (<30\u00a0mm Hg) resting LVOT gradients. Patients with latent obstruction had limiting symptoms comparable to those with more severe resting gradients and experienced a similar degree of improvement in symptoms after myectomy.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"206_CR33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jtcvs.2010.04.046","volume":"141","author":"ML Brown","year":"2011","unstructured":"Brown ML, Schaff HV, Dearani JA, Li Z, Nishimura RA, Ommen SR. Relationship between left ventricular mass, wall thickness, and survival after subaortic septal myectomy for hypertrophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg. 2011;141:439\u201343.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"206_CR34","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.jccase.2010.12.002","volume":"3","author":"RD Rothman","year":"2011","unstructured":"Rothman RD, Sadfiia MA, Lowry PA, Mela T, Abbara S, O'Callaghan C, et al. Risk stratification for sudden cardiac death after septal myectomy. J Card Cases. 2011;3:e65\u20137.","journal-title":"J Card Cases"},{"key":"206_CR35","first-page":"1515","volume":"40","author":"BA Nasseri","year":"2011","unstructured":"Nasseri BA, Stamm C, Siniawski H, Kukucka M, Komoda T, Delmo Walter EM, et al. Combined anterior mitral valve leaflet retention plasty and septal myectomy in patients with hypertrophic obstructive cardiomyopathy. Eur J Cardiothorac Surg. 2011;40:1515\u201320.","journal-title":"Eur J Cardiothorac Surg"},{"key":"206_CR36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtcvs.2010.08.011","volume":"142","author":"EA Ashikhmina","year":"2011","unstructured":"Ashikhmina EA, Schaff HV, Ommen SR, Dearani JA, Nishimura RA, Abel MD. Intraoperative direct measurement of left ventricular outflow tract gradients to guide surgical myectomy for hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 2011;142:53\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"206_CR37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1106468","volume":"366","author":"JH Kim","year":"2012","unstructured":"Kim JH, Malhotra R, Chiampas G, d\u2019Hemecourt P, Troyanos C, Cianca J, et al. Cardiac arrest during long-distance running races. N Engl J Med. 2012;366:130\u201340.","journal-title":"N Engl J Med"},{"key":"206_CR38","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.0000128363.85581.E1","volume":"109","author":"BJ Maron","year":"2004","unstructured":"Maron BJ, Chaitman BR, Ackerman MJ, Bayes de Luna A, Corrado D, Crosson JE, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004;109:2807\u201316.","journal-title":"Circulation"},{"key":"206_CR39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.hrthm.2010.10.010","volume":"8","author":"A Berruezo","year":"2011","unstructured":"Berruezo A, Vatasescu R, Mont L, Sitges M, Perez D, Papiashvili G, et al. Biventricular pacing in hypertrophic obstructive cardiomyopathy: a pilot study. Hear Rhythm. 2011;8:221\u20137.","journal-title":"Hear Rhythm"},{"key":"206_CR40","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.amjcard.2010.06.077","volume":"106","author":"JM Bos","year":"2010","unstructured":"Bos JM, Maron BJ, Ackerman MJ, Haas TS, Sorajja P, Nishimura RA, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol. 2010;106:1481\u20136.","journal-title":"Am J Cardiol"},{"key":"206_CR41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/hrt.2010.217182","volume":"98","author":"C O'Mahony","year":"2012","unstructured":"O'Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart. 2012;98:116\u201325. This study describes clinical outcomes in 334 patients with HCM and risk of SCD who underwent ICD implantation. Inappropriate shocks and\/or implant complications were seen in 30\u00a0% of patients. These results highlight the need for optimization of patient selection algorithms for ICD implantation,and for meticulous ICD programming to minimize inappropriate shocks.","journal-title":"Heart"},{"key":"206_CR42","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ahj.2007.06.026","volume":"154","author":"JJ You","year":"2007","unstructured":"You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. Life expectancy gains and cost-effectiveness of implantable cardioverter\/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. 2007;154:899\u2013907.","journal-title":"Am Heart J."},{"key":"206_CR43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1542-474X.2005.00070.x","volume":"10","author":"I Goldenberg","year":"2005","unstructured":"Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W. Cost-effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005;10:67\u201383.","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"206_CR44","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","volume":"45","author":"MV Sherrid","year":"2005","unstructured":"Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:1251\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"206_CR45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/europace\/euq434","volume":"13","author":"JW McCready","year":"2011","unstructured":"McCready JW, Smedley T, Lambiase PD, Ahsan SY, Segal OR, Rowland E, et al. Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation. Europace. 2011;13:355\u201361. This position paper from a working group of the National Heart, Lung, and Blood Institute identifies research initiatives that are expected to lead to novel therapeutic approaches for patients with HCM.","journal-title":"Europace"},{"key":"206_CR46","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/CIRCULATIONAHA.110.950089","volume":"122","author":"T Force","year":"2010","unstructured":"Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation. 2010;122:1130\u20133.","journal-title":"Circulation"},{"key":"206_CR47","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","volume":"122","author":"K Abozguia","year":"2010","unstructured":"Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562\u20139.","journal-title":"Circulation"},{"key":"206_CR48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1540-8183.2010.00605.x","volume":"24","author":"A Oto","year":"2011","unstructured":"Oto A, Aytemir K, Okutucu S, Kaya EB, Deniz A, Cil B, et al. Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy. J Interv Cardiol. 2011;24:77\u201384.","journal-title":"J Interv Cardiol"},{"key":"206_CR49","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jacc.2010.07.055","volume":"57","author":"T Lawrenz","year":"2011","unstructured":"Lawrenz T, Borchert B, Leuner C, Bartelsmeier M, Reinhardt J, Strunk-Mueller C, et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6\u00a0months' follow-up in 19 patients. J Am Coll Cardiol. 2011;57:572\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"206_CR50","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.jacc.2011.09.020","volume":"58","author":"N Sreeram","year":"2011","unstructured":"Sreeram N, Emmel M, de Giovanni JV. Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children. J Am Coll Cardiol. 2011;58:2501\u201310.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-012-0206-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-012-0206-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-012-0206-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T11:32:20Z","timestamp":1562153540000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-012-0206-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1007\/s11936-012-0206-5","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,6]]}}}